Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in older patients with newly diagnosed B-precursor ALL
NCT03480438Phase 2Completed
- Sponsor
- Goethe University Frankfurt
- Start
- Jun 2018
- Primary completion
- Jan 2024
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Goethe University Frankfurt. Started Jun 2018; status: completed.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03480438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03480438.